ReNeuron updates on ophthalmology programmes

ReNeuron Group has reported very significant positive developments with its retinal disease programme.

"The successful development of a cryopreserved formulation of our hRPC retinal cell therapy candidate enables an expansion of our clinical programmes in ophthalmology and also gives ReNeuron a significant commercial advantage in terms of prospective cost of goods and ease of use of a retinal disease therapy," said CEO Olav Hellebo.

"The expansion of our retinal disease programmes into cone-rod dystrophy and the enlargement of the Phase II part of the ongoing clinical trial in retinitis pigmentosa reflect our strong belief in the potential of our hRPC platform to benefit patients severely affected by retinal diseases where no effective treatments are currently available."

At 9:49am: (LON:RENE) ReNeuron Group PLC share price was +0.08p at 2.18p